Twelve-year follow-up of a randomized trial comparing cisplatin and cyclophosphamide with cisplatin, doxorubicin and cyclophosphamide in patients with advanced epithelial ovarian cancer

International Journal of Gynecological Cancer

Volumn 6, Issue 4, 1996, Pages 286-290

  Gadducci, A ^a   Bruzzone, M ^b   Carnino, F ^c   Ragni, N ^d   Rubagotti, A ^b   Conte, P F ^e  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c S ANNA HOSPITAL   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e UNIVERSITY OF PISA   (Italy)

Author keywords

chemotherapy; cisplatin; doxorubicin; ovarian cancer

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL;

EID: 0030017681     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.1996.06040286.x     Document Type: Article

References (21)

1. Hoskins WJ, Rubin SC. Surgery in the treatment of patients with advanced ovarian cancer. Semin Oncol 1991; 18: 213-21.
2. Ozols RF, Young RC. Chemotherapy of ovarian cancer. Semin Oncol 1991; 18: 222-31.
3. Advanced Ovarian Cancer Trialist Group. Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Br Med J 1991; 303: 884-93.
4. Neijt JP, ten Bokkel Huinink WW, van der Burg ME, et al. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 vs CP) in advanced ovarian carcinoma. J Clin Oncol 1987; 5: 1157-68.
5. Edmonson JH, McCormack GW, Fleming TR, et al. Comparison of cyclophosphamide plus cisplatin versus hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin in combination as initial chemotherapy for stage III and IV ovarian carcinomas. Cancer Treat Rep 1985; 69: 1243-8.
6. Bertelsen K, Jacobsen A, Andersen JE, et al. A randomized study of cyclophosphamide and cisplatin with or without doxorubicin in advanced ovarian cancer. Gynecol Oncol 1987; 26: 161-9.
7. Gruppo Interegionale Cooperativo Oncologico Ginecologia. Randomized comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/ cisplatin in advanced ovarian cancer. Lancet 1987; 2: 353-9.
8. Omura G, Bundy BM, Berek JS, Curry S, Delgado G, Mortel R. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 1989; 7: 457-65.
9. Conte PF, Bruzzone M, Chiara S, et al. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin and cyclophosphamide in advanced ovarian cancer. J Clin Oncol 1986; 4: 965-71.
10. The Ovarian Cancer Meta-analysis Group. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. J Clin Oncol 1991; 9: 1668-74.
11. Gruppo Interegionale Cooperativo Oncologico Ginecologia. Long-term results of a randomized trial comparing cisplatin, with cisplatin and cyclophosphamide with cisplatin, cyclophosphamide, and adriamycin in advanced ovarian cancer. Gynecol Oncol 1992; 45: 115-17.
12. Louie KG, Ozols RF, Myers CE, et al. Long-term survival results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma. J Clin Oncol 1986; 4: 1579-85.
13. Neijt JP, van der Burg ME, van Oosterom AT, et al. Combination chemotherapy in advanced ovarian carcinoma: the experience of the Netherlands Joint Study Group for Ovarian Cancer. In: Conte PF, Ragni N, Rosso R, Vermorken JB, eds. Multimodal Treatment of Ovarian Cancer. New York: Raven Press, 1989: 227-35.
14. Friedlander ML, Dembo AJ. Prognostic factors in ovarian cancer. Semin Oncol 1991; 18: 205-12.
15. A'Hern RP, Gore ME. Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol 1995; 13: 726-32.
16. McGuire WP, Hoskins WJ, Brady MF, Homesley HD, Clarke-Pearson DL. The Gynecologic Oncology Group (GOG). A Phase III trial of dose intense (DI) versus standard dose (DS) cisplatin (CDDP) and cytosan (CTX) in advanced ovarian cancer (AOC). Proc Am Soc Clin Oncol 1992; 11: Abstract 718.
17. Colombo N, Pittelli MR, Parma G, et al. Cisplatin (C) dose intensity in advanced ovarian cancer (AOC): a randomized study of conventional dose (DC) vs dose-intense (DI) cisplatin monochemotherapy. Proc Am Soc Clin Oncol 1993; 12: Abstract 806.
18. Conte PF, Bruzzone M, Gadducci A, et al. High doses vesus standard doses of cisplatin (P) in combination with epidoxorubicin (E) and cyclophosphamide (CTX) in advanced ovarian cancer (AOC) patients (PTS) with bulky residual disease: a randomized trial. Proc Am Soc Clin Oncol 1993; 12: Abstract 880.
19. Bolis G, Favalli G, Giardina G, et al. A multicentric randomized trial comparing weekly platinum (PW) vs cyclophosphamide plus platinum (CP) in advanced ovarian cancer (AOC). Proc Am Soc Clin Oncol 1994; 13: Abstract 820.
20. Kaye SB, Lewis CR, Paul J, et al. Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet 1992; 340: 329-33.
21. Ngan HY, Choo YC, Cheung M, et al. A randomized study of high-dose vs low-dose cisplatin combined with cyclophosphamide in the treatment of advanced ovarian carcinoma. Chemotherapy 1989; 35: 221-27.